"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

Shares of Teva Pharmaceutical Industries ( TEVA -13.03%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p ...

Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call. My name ...

BofA analyst Jason Gerberry lowered the firm’s price target on Teva (TEVA) to $23 from $26 and keeps a Buy rating on the shares. For FY25, the ...

Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

Teva Pharmaceutical Industries Ltd. (TEVA) has seen a decline of 13.92 percent in its stock value during Wednesday afternoon trading ...

Falling -11.7% today, shares of Teva Pharmaceutical Industries are giving us reason to question their average rating of buy. Did analysts get things wrong about this stock? Let's dive into the numbers ...

Teva stock retreated Wednesday after the pharmaceutical company reported a drop in fourth-quarter revenue.

European shares were mostly higher today. The eurozone's STOXX 600 rose 0.50%, Germany's DAX 40 gained 0.97% and France's CAC ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...

Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug ...

Wealth host Brad Smith analyzes the latest earnings reports from Wall Street. VF Corp's (VFC) stock climbed following ...